1. Home
  2. RDCM vs INDP Comparison

RDCM vs INDP Comparison

Compare RDCM & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Radcom Ltd.

RDCM

Radcom Ltd.

HOLD

Current Price

$10.23

Market Cap

172.2M

Sector

Technology

ML Signal

HOLD

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

HOLD

Current Price

$1.06

Market Cap

171.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RDCM
INDP
Founded
1985
2000
Country
Israel
United States
Employees
N/A
N/A
Industry
Computer peripheral equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
172.2M
171.9M
IPO Year
1999
2021

Fundamental Metrics

Financial Performance
Metric
RDCM
INDP
Price
$10.23
$1.06
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$18.00
N/A
AVG Volume (30 Days)
173.8K
103.7K
Earning Date
05-13-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$11.50
N/A
Revenue Next Year
$9.74
N/A
P/E Ratio
$16.35
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.40
$0.92
52 Week High
$16.74
$8.57

Technical Indicators

Market Signals
Indicator
RDCM
INDP
Relative Strength Index (RSI) 29.89 28.58
Support Level $9.40 $0.92
Resistance Level $13.27 $3.00
Average True Range (ATR) 0.43 0.21
MACD -0.07 -0.04
Stochastic Oscillator 20.83 2.58

Price Performance

Historical Comparison
RDCM
INDP

About RDCM Radcom Ltd.

Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

Share on Social Networks: